NCT03247582View on ClinicalTrials.gov

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)

CompletedOBSERVATIONAL
Enrollment

234

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

May 3, 2022

Study Completion Date

May 3, 2022

Conditions
Atrial Fibrillation
Interventions
DRUG

Edoxaban

Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).

Trial Locations (4)

Unknown

Prince of Wales Hospital (1082), Hong Kong

Prince of Wales Hospital (1083), Hong Kong

Queen Mary Hospital, Department of Cardiology (1801), Hong Kong

Queen Mary Hospital, Department of Neurology (1805), Hong Kong

All Listed Sponsors
lead

Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company

INDUSTRY

NCT03247582 - Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong) | Biotech Hunter | Biotech Hunter